Sugi Predict

Sugi Predict / Compounds / SCHEMBL987839

SCHEMBL987839

SCHEMBL987839

COC(=O)c1cnc(I)c(O)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 5/20 0.53
▸ LMNA P02545 3/20 0.53
▸ XDH P47989 2/20 0.53
▸ L3MBTL1 Q9Y468 2/20 0.53
▸ POLB P06746 1/20 0.53
▸ GAA P10253 1/20 0.53
▸ NFKB1 P19838 1/20 0.53
▸ GFER P55789 1/20 0.53
▸ NFKB2 Q00653 1/20 0.53
▸ RELA Q04206 1/20 0.53
▸ FUT7 Q11130 1/20 0.53
▸ TDP1 Q9NUW8 1/20 0.53
▸ CA12 O43570 3/20 0.50
▸ CA1 P00915 3/20 0.50
▸ CA2 P00918 3/20 0.50
▸ CA7 P43166 3/20 0.50
▸ CA9 Q16790 3/20 0.50
▸ CA14 Q9ULX7 3/20 0.50
▸ MAPK1 P28482 2/20 0.47
▸ ATM Q13315 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18348293 0.82 ATM (0.51) KDM4ELMNAXDHL3MBTL1POLB
SCHEMBL25049604 0.81 CA12 (0.54) LMNATDP1CA12CA1CA2
SCHEMBL30415121 0.81 MAPK1 (0.50) KDM4ELMNAXDHL3MBTL1POLB
SCHEMBL5819835 0.81 KDM4E (0.49) KDM4ELMNAXDHL3MBTL1POLB
SCHEMBL10131341 0.81 MAPT (0.46) KDM4ELMNAXDHL3MBTL1POLB
SCHEMBL31629408 0.81 MAPK1 (0.46) KDM4ELMNAXDHL3MBTL1POLB
SCHEMBL335107 0.81 MAPK1 (0.50) KDM4ELMNAXDHL3MBTL1POLB
SCHEMBL17703486 0.80 KDM4E (0.55) KDM4ELMNAXDHL3MBTL1POLB
SCHEMBL10201046 0.79 CA5A (0.40) KDM4ELMNAXDHL3MBTL1POLB
SCHEMBL72042 0.79 KDM4E (0.53) KDM4ELMNAXDHL3MBTL1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12358910-B2 Heteroaromatic compounds as Vanin inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2025-07-15 — — US disclosed
CN-113166117-B Heteroaromatic compounds as VANIN inhibitors 勃林格殷格翰国际公司 2025-04-15 — — CN disclosed
US-12240828-B2 Heteroaromatic compounds as vanin inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2025-03-04 — — US disclosed
WO-2025039999-A1 FUSED HETEROARYL COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE 江苏恒瑞医药股份有限公司 2025-02-27 — — WO disclosed
EP-3890828-B1 HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2025-02-19 — — EP disclosed
CN-113226462-B Heteroaromatic compounds as VANIN inhibitors 勃林格殷格翰国际公司 2025-02-11 — — CN disclosed
CN-113788825-B Heteroaromatic compounds as VANIN inhibitors 勃林格殷格翰国际有限公司 2024-06-04 — — CN disclosed
CN-114478485-B Heteroaromatic compounds as VANIN inhibitors 勃林格殷格翰国际有限公司 2024-04-05 — — CN disclosed
WO-2024020170-A1 ARYL HYDROCARBON RECEPTOR AGONIST PRODRUGS AND METHODS OF USE THEREOF ALLIANTHERA (SUZHOU) BIOPHARMACEUTICAL CO., LTD. (CN) 2024-01-25 — — WO disclosed
US-11795165-B2 Tetrahydro-benzoazepine glycosidase inhibitors ASCENEURON SA (CH) 2023-10-24 — — US disclosed
US-7928248-B2 Benzopyran and benzoxepin PI3K inhibitor compounds and methods of use GENENTECH, INC. (US) 2011-04-19 — — US disclosed
US-7928248-B2 Benzopyran and benzoxepin PI3K inhibitor compounds and methods of use GENENTECH, INC. (US) 2011-04-19 — — US disclosed
WO-2011036280-A1 BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2011-03-31 — — WO disclosed
US-20110076292-A1 BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2011-03-31 — — US disclosed
EP-2276767-A1 BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE Genentech, Inc. (US) 2011-01-26 — — EP disclosed
WO-2009123971-A1 BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2009-10-08 — — WO disclosed
WO-2009123971-A1 BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2009-10-08 — — WO disclosed
US-20090247567-A1 BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2009-10-01 — — US disclosed
US-20090247567-A1 BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2009-10-01 — — US disclosed
US-20090247567-A1 BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2009-10-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12240828-B2 Heteroaromatic compounds as vanin inhibitors VHL, FANCI, PAH KDM4E 3614/4885LMNA 2437/4885XDH 527/4885
US-12358910-B2 Heteroaromatic compounds as Vanin inhibitors VHL, FANCI, PAH KDM4E 3614/4885LMNA 2437/4885XDH 527/4885
US-20110076292-A1 BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE BMX, PIK3CA, PI4KA KDM4E 3058/4885LMNA 1594/4885XDH 1075/4885
US-20090247567-A1 BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE PIK3CA, BMX, PIK3CD KDM4E 3381/4885LMNA 654/4885XDH 345/4885
US-11795165-B2 Tetrahydro-benzoazepine glycosidase inhibitors BACE1, BACE2, BCHE KDM4E 2012/4885LMNA 324/4885XDH 502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.